CJC-1295 / Ipamorelin Blend 5mg/5mg
This premium research blend combines CJC-1295 (a long-acting GHRH analog with Drug Affinity Complex/DAC modification) and Ipamorelin (a selective GHS-R1a agonist). CJC-1295 DAC's extended half-life (approximately 6–8 days) provides sustained GHRH receptor stimulation, while Ipamorelin provides complementary GHS-R1a activation.
Research with this combination has investigated sustained GH pulse augmentation, IGF-1 elevation, and body composition changes in animal models.
Specifications: CJC-1295 5mg + Ipamorelin 5mg | Lyophilized | Purity ≥99% each | Store at −20°C
For Research Use Only. Not for human or veterinary use. This product is intended solely for in vitro and laboratory research. Not approved by the FDA. Not a drug, food, or cosmetic. Keep out of reach of children.
